Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SASH1 S519N Variant Links Skin Hyperpigmentation and Premature Hair Graying to Dysfunction of Melanocyte Lineage.
Lambert KA, Clements CM, Mukherjee N, Pacheco TR, Shellman SX, Henen MA, Vögeli B, Goldstein NB, Birlea S, Hintzsche J, Caryotakis G, Tan AC, Zhao R, Norris DA, Robinson WA, Wang Y, VanTreeck JG, Shellman YG. Lambert KA, et al. Among authors: pacheco tr. J Invest Dermatol. 2025 Jan;145(1):144-154.e3. doi: 10.1016/j.jid.2024.04.027. Epub 2024 Jun 6. J Invest Dermatol. 2025. PMID: 38848986 Free PMC article.
SASH1 interacts with TNKS2 and promotes human melanocyte stem cell maintenance.
Lambert KA, Clements CM, Mukherjee N, Pacheco TR, Shellman SX, Henen MA, Vögeli B, Goldstein NB, Birlea S, Hintzsche J, Tan AC, Zhao R, Norris DA, Robinson WA, Wang Y, VanTreeck JG, Shellman YG. Lambert KA, et al. Among authors: pacheco tr. bioRxiv [Preprint]. 2023 Sep 27:2023.09.26.559624. doi: 10.1101/2023.09.26.559624. bioRxiv. 2023. PMID: 37808724 Free PMC article. Preprint.
Exploring new pathways in endocrine-resistant breast cancer.
de Pinho IS, Abreu C, Gomes I, Casimiro S, Pacheco TR, de Sousa RT, Costa L. de Pinho IS, et al. Among authors: pacheco tr. Explor Target Antitumor Ther. 2022;3(3):337-361. doi: 10.37349/etat.2022.00086. Epub 2022 Jun 20. Explor Target Antitumor Ther. 2022. PMID: 36045911 Free PMC article. Review.
Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer.
Cruz-Duarte R, Rebelo de Almeida C, Negrão M, Fernandes A, Borralho P, Sobral D, Gallego-Paez LM, Machado D, Gramaça J, Vílchez J, Xavier AT, Ferreira MG, Miranda AR, Mansinho H, Brito MJ, Pacheco TR, Abreu C, Lucia-Costa A, Mansinho A, Fior R, Costa L, Martins M. Cruz-Duarte R, et al. Among authors: pacheco tr. Clin Cancer Res. 2022 Mar 15;28(6):1203-1216. doi: 10.1158/1078-0432.CCR-21-1992. Clin Cancer Res. 2022. PMID: 34980600 Free PMC article.
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Verma S, et al. Circulation. 2021 Dec 7;144(23):1845-1855. doi: 10.1161/CIRCULATIONAHA.121.056290. Epub 2021 Oct 28. Circulation. 2021. PMID: 34710343 Free article. Clinical Trial.
Increased inflammatory biomarkers and changes in biological rhythms in bipolar disorder: A case-control study.
Bavaresco DV, da Rosa MI, Uggioni MLR, Ferraz SD, Pacheco TR, Toé HCZD, da Silveira AP, Quadros LFA, de Souza TD, Varela RB, Vieira AAS, Pizzol FD, Valvassori SS, Quevedo J. Bavaresco DV, et al. Among authors: pacheco tr. J Affect Disord. 2020 Jun 15;271:115-122. doi: 10.1016/j.jad.2020.03.073. Epub 2020 Apr 19. J Affect Disord. 2020. PMID: 32479306
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Bhatt DL, et al. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415628 Clinical Trial.
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators. Ridker PM, et al. N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304242 Free article. Clinical Trial.
Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases.
Ferreira AR, Bettencourt M, Alho I, Costa AL, Sousa AR, Mansinho A, Abreu C, Pulido C, Macedo D, Vendrell I, Pacheco TR, Costa L, Casimiro S. Ferreira AR, et al. Among authors: pacheco tr. J Bone Oncol. 2017 Jan 28;6:16-21. doi: 10.1016/j.jbo.2017.01.002. eCollection 2017 Mar. J Bone Oncol. 2017. PMID: 28194325 Free PMC article.
34 results